BOOKMARK
  • Korean|
  • Chinese|
  • Japanese|
  • Vietnamese
본문내용 바로가기

Aju Business Daily

SEARCH
  • ECONOMY
  • ENTERTAINMENT
  • IT
  • South Korea
  • North Korea
  • WORLD
  • SPORTS
  • LIFESTYLE
  • AUTO MOTIVE
  • OPINION
  • PEOPLE
  • MILITARY
Home > Health > article

Celltrion ready to sell antigen diagnostic kit for rapid and accurate COVID-19 screening

Lim Chang-won Reporter(cwlim34@ajunews.com) | Posted : June 16, 2020, 13:39 | Updated : June 16, 2020, 13:39
  • 트위터
  • 페이스북
  • 웨이보

[Courtesy of Celltrion]


SEOUL -- Celltrion, a South Korean bio firm involved in the development of anti-body treatment, is ready to roll out a highly sensitive and accurate antigen diagnostic kit that can yield results in 20 minutes. The kit provides both the speed of existing rapid diagnostic kits and the high sensitivity of molecular diagnosis so that COVID-19 patients can be sorted out in the early stages of infection.
 
Celltrion said that it has completed the development of a point-of-care antigen testing kit for COVID-19 together with BBB, a South Korean company that specializes in blood testing and lab-on-a-chip technology. The kit is a portable device to support the early detection of COVID-19 patients in clinical settings.
 
The real-time polymerase chain reaction (RT-PCR) method that amplifies specific DNA samples and takes at least six hours to get results has been used widely in South Korea due to its reliability. Celltrion said its method showed a high sensitivity of more than 95 percent compared to RT-PCR, making it the highest level of completion among existing rapid diagnostic kits.
 
The antigen testing kit uses a microfluidic electrochemical biosensor which aims to give fast and accurate results, Celltrion said, adding it can show results within 15-20 minutes.
 
Celltrion said the antigen testing kit would seek a CE mark in Europe later this month, ahead of the expected launch in July. CE marking is a certification mark that indicates conformity with health, safety, and environmental protection standards for products sold within the European Economic Area.
 
Separately, Celltrion forged a distribution agreement with Humasis, an in vitro diagnostic medical device manufacturer in South Korea, to sell a rapid antibody diagnostic test kit globally this month. The kit can be used by hospitals to confirm patients to be discharged.
 
Celltrion and Humasis will cooperate in the development of an upgraded rapid antibody diagnostic test and a rapid antigen diagnostic test. Celltrion said it would leverage its advanced therapeutic technologies to expand the range of co-developed diagnostic devices beyond COVID-19 to other infectious diseases through cooperation with Humasis.
 
"We are keen to drive early diagnosis of COVID-19 through the availability of our testing portfolio," said Celltrion's R&D unit head Kwon Ki-sung. "We are committed to providing flexibility for testing needs as the pandemic evolves, and are using our expertise and past experience developing antibody treatments and targeting coronaviruses to fight this pandemic."
 

  • Lim Chang-won Reporter
  • email : cwlim34@ajunews.com
© Aju Business Daily & www.ajunews.com Copyright: All materials on this site may not be reproduced, distributed, transmitted, displayed, published or broadcast without the authorization from the Aju News Corporation.
  • twitter
  • facebook
  • weibo
  • link copy
  • LIST
  • TOP

Related news

  • .Celltrions antibody COVID-19 treatment wins approval from S. Korean state watchdog.
    Celltrion's antibody COVID-19 treatment wins approval from S…
  • .Canada approves Celltrions subcutaneous injection for rheumatoid arthritis indication .
    Canada approves Celltrion's subcutaneous injection for rheum…
  • .State watchdog starts screening Celltrions antibody treatment for COVID-19.
    State watchdog starts screening Celltrion's antibody treatme…
  • .Celltrion leaves door open for consignment production of COVID-19 vaccines.
    Celltrion leaves door open for consignment production of COV…
  • .GC Pharmas plasma treatment allowed for actual use in treating COVID-19 patients.
    GC Pharma's plasma treatment allowed for actual use in treat…

Real Time Photo News

  • .BTS agency posts record earnings in 2020 on brisk online activities and album sales .

    BTS agency posts record earnings in 2020 on brisk online activities and album sales

  • .[FOCUS] BTS agency leagues with Universal Music to launch new K-pop band in US music scene.

    [FOCUS] BTS agency leagues with Universal Music to launch new K-pop band in US music scene

  • .CJ ENM aims to become major visual content producer thru partnership with Epic Games .

    CJ ENM aims to become major visual content producer thru partnership with Epic Games

  • .​Solo singer Sunmi to come back with new album Tail.

    ​Solo singer Sunmi to come back with new album 'Tail'

  • .Big Hits live-streaming joint venture gains reinforcements from Universal Music, YG.

    Big Hit's live-streaming joint venture gains reinforcements from Universal Music, YG

Latest News

more+

  • Prime Minister Chung stresses importance of 'borderless communication channel' to minimize informati…
  • State hospital succeeds in inserting wireless pacemakers into hearts of bradyarrhythmia patients
  • LG Electronics' joint venture with Canada's Magna awaits approval by shareholders in March
  • Sajo Seafood to launch raw tuna menu delivery service
  • Researchers find new roundworm species near Dokdo
Aju Business Daily
  • ABOUT US
  • CONTACT US
  • PRIVACY STATEMENT
  • Copyright Policy

Address : Aju News Corporation LEEMA Building, 11th floor, 42, Jong-ro 1-gil, Jongno-gu, Seoul.    Mail : swatchsjp@ajunews.com

Copyright ⓒ 2016 By Ajunews Corporation, All Rights Reserved.

Mobile view